24 -4 (54) 2023 — Gozieva Sh.S. — OPTIMIZATION OF PREVENTION METHODS IN PREGNANT WOMEN WITH HYPERTENSIVE DISORDERS

OPTIMIZATION OF PREVENTION METHODS IN PREGNANT WOMEN WITH HYPERTENSIVE DISORDERS

Gozieva Sh.S. Andijan State Medical Institute Uzbekistan

Resume

Preeclampsia is one of the unresolved obstetric problems due to the wide spread, insufficient effectiveness of complex therapy, often with adverse pregnancy outcomes for the mother and fetus. Key words: hypertensive disorders, preeclampsia, low molecular weight heparin.

First page

113

Last page

116

For citation: Gozieva Sh.S. – OPTIMIZATION OF PREVENTION METHODS IN PREGNANT WOMEN WITH HYPERTENSIVE DISORDERS //New Day in Medicine 4(54)2023 113-116 https://goo.su/H5PB

LIST OF REFERENCES:

  1. Waterstone M, Bewley S, Wolfe C. Incidence and predictors of severe obstetric morbidity. Case-control study // BMJ. 2011;3(22):1089-1094.
  2. AWMF-Leitlinie 015/018, 2017. Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen.[Электронный ресурс]
  3. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy // Am. J. Obstet. Gynaecol. 2018;142:159-167.
  4. Redmann C., Sargent I. Latest Advances in Understanding Preeclampsia // Science. 2015;308:1592-1594.
  5. Stepan H., Geipel A., Schwarz F. et al. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion // Am. J. Obstet. Gynecol. 2018;198:175-176.
  6. During P. Hypertensive Schwangerschaftserkrankungen. In: Die Geburtshilfe, Hrsg. H. Schneider, P. Husslein, KTM. Schneider. Springer -Verlag Berlin Heidelberg New York, 2014;302.
  7. Conde-Agudelo A., Villar J., Lindheimer M. World Health Organisation systematic review of screening tests for preeclampsia // Obstet. Gynecol. 2014;104:1367-1391.
  8. Dekker G., Sibai B. Primary, and tertiary prevention of preeclampsia // Lancet. 2011;357:209-215.
  9. Askie L.M., Duley L., Henderson-Smart D.J., Stewart L.A. On behalf of the PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data // Lancet. 2017;369:1791-1798.
  10. Rumbold A., Duley L., Crowther C.A., Haslam R.R. Antioxidants for preventing pre-eclampsia. Cochrane Database of Systematic Reviews 2018; Issue 1. Art. No.: CD004227. DOI: 10.1002/14651858.CD004227.pub3.
  11. Brown M.A., Buddie M.L., Farrell T., et al. Randomised trial of management of hypertensive pregnancies by Korotkoff phase IV or phase V. Lancet 2020;352:777-781.
  12. Thangaratinam S., Coomarasamy A., O’Mahony F. et al. Estimation of proteinuria as a predictor of complications of preeclampsia: a systematic review. // BMC Medicine 2009;7:10. doi:10.1186/1741-7015-7-10.
  13. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia // Lancet. 2015;36:785-799.
  14. Abalos E., Duley L., Steyn D.W., Henderson-Smart D.J. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy // Cochrane Database Syst. Rev. 2011;2:CD002252.
  15. Dadelszen von P., Omstein M.P., Bull S.B. et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis // Lancet. 2010;355:87-92.
  16. Бондаренко К.Р., Мавзютов А.Р., Озолиня Л.А. Диагностическое значение лабораторных маркеров системной эндотоксинемии при преэклампсии (гестозе) // Мать и дитя: материалы XIV Всерос. научного форума. -М., 2013; 27-28.

file

download